Corporate Update January 2024 Developing Therapeutic Antibodies Targeting Allergic, Inflammatory and Proliferative Disease Disclaimer This presentation contains forward-looking statements. All statements other than statements of historical fact contained in this presentation, including statements regarding the financial position of Allakos Inc. ("Allakos," the "Company," "we" or "our"); estimated lirentelimab closeout, severance and other costs; the timing of payment of restructuring expenditures; estimated ...

Allakos (ALLK) Update / Briefing January 16, 2024 08:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by. Welcome to LearnTelomob Phase II chronic spontaneous urticaria and atopic dermatitis results. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withd ...